about
Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.Phosphorylated STAT5 regulates p53 expression via BRCA1/BARD1-NPM1 and MDM2.Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer.The evolving first-line treatment of advanced non-small cell lung cancer harbouring epidermal growth factor receptor mutations.Targeting Polo-like kinase 1 and TRAIL enhances apoptosis in non-small cell lung cancer.Production of a mono-biotinylated EGFR nanobody in the E. coli periplasm using the pET22b vectorTargeting the tyrosine kinase inhibitor-resistant mutant EGFR pathway in lung cancer without targeting EGFR?CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibitionSingle-domain antibody fusion proteins can target and shuttle functional proteins into macrophage mannose receptor expressing macrophages
P50
Q36772036-A6C74D4B-2059-4815-B871-C6FC4388A1DFQ38724800-96BF371F-873A-4300-AF2F-A353E7494EAEQ41694346-796FD85E-6FB8-473A-98F1-133E200FBE2EQ54115748-8A7F50B2-9DBE-4BD1-AF86-1DC0CCB47B57Q55343368-E148D165-53AC-4D8E-892F-5520EA8A53C5Q55504441-81265A32-0738-484C-A22E-E324ECBC3509Q57801517-A7038C9B-C3E9-4AE8-BFDF-9414D0C8A492Q90612036-E4FD7E4A-5F9F-4581-AD9B-1C532E3B245BQ91723540-A881ED27-8A3A-4BDD-8A90-D2879D773BFBQ91856680-317A9C5C-7792-4951-B286-5D89F78940C4
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Philippe Giron
@en
Philippe Giron
@nl
type
label
Philippe Giron
@en
Philippe Giron
@nl
prefLabel
Philippe Giron
@en
Philippe Giron
@nl
P31
P496
0000-0002-1331-1890